Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the hepatitis therapeutics market size evolved in recent years?

The size of the hepatitis therapeutics market has shown a consistent increase over the past few years. Expected to rise from $18.66 billion in 2024 to $19.27 billion in 2025, the market will showcase a compound annual growth rate (CAGR) of 3.2%. Factors including the development of vaccines, antiviral drugs, public health strategies, research investment, and emergent treatments have all contributed to this growth during the historic period.

What are the predictions for the hepatitis therapeutics market size in the coming years?

In the coming years, the hepatitis therapeutics market is projected to experience consistent growth, reaching $22.75 billion in 2029 with a compound annual growth rate (CAGR) of 4.2%. The anticipated growth during this period can be attributed to ongoing research and development, international health campaigns, alterations in patient care approaches, government programs, and increasing awareness of the disease. Key trends predicted for this period include patient advocacy and support, continuous oversight and follow-up, parity in healthcare, the use of telemedicine and remote care, and prioritizing the elimination of hepatitis C.

Get your hepatitis therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

What key factors are fueling the growth of the hepatitis therapeutics market?

The expansion of the hepatitis therapeutic market is being driven by the global increase in hepatitis infections. This surge is primarily due to inadequate healthcare access and lack of vaccinations, coupled with a rise in the use of intravenous drugs, unsafe blood transfusion practices, and poor sanitation and hygiene conditions in certain regions globally. For example, in April 2022, the World Health Organization (WHO), a United States-based United Nations public health agency, reported from 11 nations at least 169 cases of acute hepatitis of unknown origin. Furthermore, around 350 million people globally are carriers of viral hepatitis B or C, but a large proportion of these people don’t have access to testing and treatment. As a result, the increased prevalence of hepatitis infections is driving the growth of the hepatitis therapeutics market.

How is the global hepatitis therapeutics market divided into key segments?

The hepatitis therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types

2) By Drug Class: Oral Antivirals, Immune Modulators

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Hepatitis A: Vaccines, Post-Exposure Prophylaxis (PEP)

2) By Hepatitis B: Antiviral Medications, Immune Modulators, Vaccines

3) By Hepatitis C: Direct-Acting Antivirals (DAAs), Ribavirin, Interferon-Based Therapies

4) By Other Disease Types: Hepatitis D, Hepatitis E, Other Viral Hepatitis Infections

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9956&type=smp

Who are the key firms paving the way for growth in the hepatitis therapeutics market?

Major companies operating in the hepatitis therapeutics market include Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Biocon Biopharmaceuticals Pvt. Ltd.

Which trends are expected to transform the hepatitis therapeutics market?

Innovation in product development is becoming a prominent trend in the hepatitis therapeutics market. Major players in this market are introducing new products to maintain their market dominance. For example, Gilead Sciences, Inc., a biopharmaceutical firm based in the US, received FDA approval in November 2022 for a medicine named Vemlidy (tenofovir alafenamide), specifically targeted towards the treatment of pediatric patients suffering from chronic hepatitis B virus infection. Initially approved by the FDA in 2016, Vemlidy is a specially designed prodrug of tenofovir that is a recommended daily treatment for those battling chronic hepatitis B virus infection and compensated liver disease, as per the guidelines from the American Liver Foundation. It is positioned as a preferred or first-line treatment option for patients dealing with chronic HBV and compensated liver condition.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9956

What regions are contributing significantly to the growth of the hepatitis therapeutics market?

North America was the largest region in the hepatitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Healthcare/Medical Simulation Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/healthcare-medical-simulation-global-market-report

Healthcare BPO Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/healthcare-bpo-global-market-report

Healthcare Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/healthcare-service-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: